£1.0M
The early cancer diagnostic specialist received backing from existing investor Deepbridge Capital alongside leadership changes.
Z
Zilico
Zilico develops medical diagnostic technology for early cancer detection.
£1.0MTotal raised
Zilico develops medical diagnostic technology for early cancer detection using its proprietary Electrical Impedance Spectroscopy platform. The firm originated from research at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Zilico's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
SK
Sameer Kothari
Chief Executive
Sameer brings extensive leadership experience, having previously served as chief executive of Zilico Limited and Plasso Technology Limited. He also held commercial and strategy roles at Health Innovation Manchester and Marconi.
LinkedIn
Andrew Newell
Chair
Andrew brings medical technology executive and board experience, with a background in funding and US operations. He currently chairs Zilico alongside advisory and directorial roles at Applied Monitoring, Somnus Scientific, and Cipher Surgical.
LinkedInAF
Alan Folwell
Board Member
JM
Jerry Mobbs
Board Member
TM
Tony Miao
Board Member